Skip to main content
Journal cover image

Clinical Trials Versus Clinical Practice: When Evidence and Practice Diverge--Should Nondiabetic Patients With 3-Vessel Disease and Stable Ischemic Heart Disease Be Preferentially Treated With CABG?

Publication ,  Journal Article
Kansara, P; Weiss, S; Weintraub, WS; Hann, MC; Tcheng, J; Rab, ST; Klein, LW; Interventional Council of the American College of Cardiology,
Published in: JACC Cardiovasc Interv
November 2015

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JACC Cardiovasc Interv

DOI

EISSN

1876-7605

Publication Date

November 2015

Volume

8

Issue

13

Start / End Page

1647 / 1656

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Stents
  • Risk Factors
  • Risk Assessment
  • Registries
  • Practice Patterns, Physicians'
  • Practice Guidelines as Topic
  • Percutaneous Coronary Intervention
  • Patient Selection
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kansara, P., Weiss, S., Weintraub, W. S., Hann, M. C., Tcheng, J., Rab, S. T., … Interventional Council of the American College of Cardiology, . (2015). Clinical Trials Versus Clinical Practice: When Evidence and Practice Diverge--Should Nondiabetic Patients With 3-Vessel Disease and Stable Ischemic Heart Disease Be Preferentially Treated With CABG? JACC Cardiovasc Interv, 8(13), 1647–1656. https://doi.org/10.1016/j.jcin.2015.07.020
Kansara, Pranav, Sandra Weiss, William S. Weintraub, Matthew C. Hann, James Tcheng, S Tanveer Rab, Lloyd W. Klein, and Lloyd W. Interventional Council of the American College of Cardiology. “Clinical Trials Versus Clinical Practice: When Evidence and Practice Diverge--Should Nondiabetic Patients With 3-Vessel Disease and Stable Ischemic Heart Disease Be Preferentially Treated With CABG?JACC Cardiovasc Interv 8, no. 13 (November 2015): 1647–56. https://doi.org/10.1016/j.jcin.2015.07.020.
Kansara, Pranav, et al. “Clinical Trials Versus Clinical Practice: When Evidence and Practice Diverge--Should Nondiabetic Patients With 3-Vessel Disease and Stable Ischemic Heart Disease Be Preferentially Treated With CABG?JACC Cardiovasc Interv, vol. 8, no. 13, Nov. 2015, pp. 1647–56. Pubmed, doi:10.1016/j.jcin.2015.07.020.
Kansara P, Weiss S, Weintraub WS, Hann MC, Tcheng J, Rab ST, Klein LW, Interventional Council of the American College of Cardiology. Clinical Trials Versus Clinical Practice: When Evidence and Practice Diverge--Should Nondiabetic Patients With 3-Vessel Disease and Stable Ischemic Heart Disease Be Preferentially Treated With CABG? JACC Cardiovasc Interv. 2015 Nov;8(13):1647–1656.
Journal cover image

Published In

JACC Cardiovasc Interv

DOI

EISSN

1876-7605

Publication Date

November 2015

Volume

8

Issue

13

Start / End Page

1647 / 1656

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Stents
  • Risk Factors
  • Risk Assessment
  • Registries
  • Practice Patterns, Physicians'
  • Practice Guidelines as Topic
  • Percutaneous Coronary Intervention
  • Patient Selection
  • Humans